Pages

Showing posts with label cardiovascular disease. Show all posts
Showing posts with label cardiovascular disease. Show all posts

Thursday, 7 March 2013

Limiting processed meat consumption 'could prevent three per cent of premature deaths'

source: http://www.nhs.uk/news/2013/03March/Pages/Diet-high-in-processed-meat-threatens-health.aspx

I conclude I should eat ave. 50g/day red meat and 20g/day processed meat; 70g/day total meat (Dept. Health guideline)

Diet high in processed meat 'threatens health'



Processed meats include bacon, sausages and salami
The big health news of the week is the claim that eating a diet high in processed meat can increase the risk of premature death due to cancer and heart disease. 
The current media scare stems from a large Europe-wide study looking at diet and mortality, involving just under half a million people who were followed for an average of 12.7 years.
One of the main findings was that people in the study who ate the most processed meat (160g or more per day) had a 44% increased risk of dying during follow-up compared to those who ate the least (10g or less).
The link to red meat was less conclusive.
The researchers estimated that if we all ate less than 20g of processed meat (which is around a single small piece of bacon) a day, then 3.3% of all deaths could be avoided – which is where the media reports came from that processed meat is responsible for 1 in 30 deaths.
However, an important limitation (rightly highlighted by the authors) is the possibility that other health and lifestyle factors could be contributing towards premature death risks.
Nevertheless, the study does highlight the importance of eating a healthy balanced diet, containing a high amount of fruit and vegetables.

Processed meat

Processed meat refers to meat that has been preserved by smoking, curing, salting or adding preservatives. This includes sausages, bacon, ham, salami and pâtés.

Processed meat is usually high in fat and cholesterol, which can increase heart disease risk. A diet high in processed meat (regularly eating more than 90g a day) has also been linked to an increased risk of bowel cancer.

This study found that people who ate more than 160g a day had the highest risk of premature death – this is equivalent to eating a full English breakfast every morning.

The Department of Health recommends that you do not eat more than 70g of red or processed meat a day.

Where did the story come from?

The study was carried out by researchers from the Institute of Social and Preventive Medicine, University of Zurich, Switzerland, and a large number of other institutions across Europe.
Financial support was provided by a range of European organisations including, government, charity and academic institutions.
The study was published in thepeer-reviewed journal BMC Medicine, which is available on an open access basis.
The media stories are generally representative of the findings of this research, with most including the common sense advice that eating an occasional bacon sarnie won’t kill you – just don’t do it every day.
The claims that processed meat is responsible for 1 in 30 deaths are based on the researchers’ estimate that 3.3% of the deaths in this study could have been prevented if all those who took part in the study ate less than 20g of processed meat a day.

What kind of research was this?

Many past observational studies have suggested that high levels of red meat and processed meat consumption could be linked to a range of diseases, including cardiovascular diseases and various cancers, such as bowel cancer.
However, it can be difficult in such studies to exclude the possibility that the effect is not directly due to red and processed meats as such, but is due to the influence of other health and lifestyle factors. For example, people who eat a small amount of red and processed meat may also be eating higher amounts of fruit and vegetables, exercising more, be less likely to be overweight, smoke, or drink excess amounts of alcohol.
In the same vein, people who eat lots of processed meat may have other unhealthy habits such as drinking lots of alcohol and being heavy smokers.
This was a large cohort study using data collected as part of the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
EPIC is an ongoing cohort study including more than 500,000 participants from 10 European countries.
The researchers took data from the EPIC study to look at the association between red meat, processed meat, and poultry meat consumption, and the risk of overall mortality and cause-specific mortality.

What did the research involve?

Men (aged 40 to 70) and women (aged 35 to 70) were recruited to EPIC between 1992 and 2000 (depending on the European study centre). After excluding those with self-reported cancer or heart disease, or those who did not report on smoking status at the time of enrolment, there were 448,568 people in the study.
Dietary assessment was performed slightly differently depending on the country:
  • seven countries gave self-administered dietary questionnaires (including data on 300-350 food items)
  • three countries administered a similar questionnaire by direct interview
  • two of the countries (UK and Sweden) also combined the questionnaires with a seven-day food diary
For the purposes of analysis, they grouped food products as follows:
  • red meat (beef, pork, mutton/lamb, horse, goat)
  • processed meat (including ham, bacon, sausages, or a small amount of minced meat as part of a ready-to-eat product – processed meat is mainly taken to be red meat, but it could be white as well)
  • white meat (poultry, including chicken, hen, turkey, duck, goose, unclassified poultry, and rabbit) 
Various other sociodemographic, health and lifestyle questions were also assessed at recruitment, including age, education, height and weight, medical history, alcohol consumption, and smoking history (current, past or never, including questions on frequency and type of tobacco smoked).
Follow-up of outcomes was to 2005-09, depending on the country, with an average follow-up of 12.7 years. Information on deaths and cause of death was obtained through record linkage with cancer registries, Boards of Health, and death indices in seven countries, and through active follow-up of participants (for example, mail, telephone, and medical records) in three countries.
Information on vital status could be obtained for 98% of the cohort, which is impressive given the size of the study.
Hazard ratios were calculated to examine the association between different types and quantities of meat and processed meat consumption and risk of death.
They adjusted analyses for the following cofounders:
  • age
  • study centre
  • weight and height
  • smoking history
  • alcohol intake
  • overall energy intake
  • physical activity levels
  • educational level

What were the basic results?

Compared to men and women who ate lower amounts of red and processed meat, those who ate the highest amounts tended to also eat fewer fruit and vegetables, be more likely to smoke, and less likely to have a university degree. Men who ate the highest amounts of red meat also drank more alcohol than those who ate lower amounts. This result was not seen in women.
During the average 12.7 year follow-up, there were 26,344 deaths (6% of the cohort), of these, 37% were due to cancer, 21% due to cardiovascular disease, 4% due to respiratory disease, 3% to digestive tract diseases, and the remainder due to various other causes.
Overall, there was a link between increasing processed meat consumption and risk of all-cause mortality. In the model adjusted for all confounders:
  • people who ate the highest amount of processed meat (160g per day) had 44% increased risk of death compared to those who ate 10-20g per day (hazard ratio (HR) 1.44, 95% confidence interval (CI) 1.24 to 1.66)
  • people who ate 80-160g a day had 21% increased risk (HR 1.21, 95% CI 1.14 to 1.28) and those who ate 40-80g a day had 9% increased risk (HR 1.09, 95% CI 1.05 to 1.14) compared to those who ate 10-20g per day
  • compared to those who ate 10-20g per day, there was no difference in risk with eating 0-10g or eating 10-40g
  • overall, eating an additional 50g of processed meat a day gave 18% increased mortality risk (HR 1.18. 95% CI 1.11 to 1.25)
  • eating an additional 50g of processed meat a day also gave a 30% increased risk of dying from any cardiovascular disease (HR 1.30, 95% CI 1.17 to 1.45), and an 11% increased risk of dying from any cancer (HR 1.11, 95% CI 1.03 to 1.21)
The link with red meat was not as strong as for processed meat:
  • eating the highest intake of red meat (160g per day) was associated with 14% increased risk of all-cause mortality compared to eating 10-20g per day (HR 1.14, 95% CI 1.01 to 1.28)
  • people who ate 20-160g of red meat a day were at no higher risk than those who ate 10-20g per day
  • people who ate the lowest amount (0-10g a day) also had increased mortality risk compared to those who ate 10-20g per day.
  • unlike with processed meat, the researchers found no overall significant increase in mortality risk for eating an additional 50g of red meat a day


There was no link between death risk and poultry consumption.
The researchers estimated that 3.3% of all deaths could be avoided if all people ate less than 20g per day of processed meat.

How did the researchers interpret the results?

The researchers conclude that their analysis supports a ‘moderate association’ between increased processed meat consumption and increased mortality, in particular due to cardiovascular diseases, but also cancer.

Conclusion

This is a useful study examining whether there is an increased risk of dying from any cause, and from specific causes, with increased consumption of red meat and processed meat. The link to red meat was less conclusive, but there appeared to be a consistent link between increasing processed meat consumption and mortality risk.
The study has many strengths, including that it followed a large number of adults from across 10 European countries for an average 12.7 years, with almost complete follow-up.
The study used reliable methods to assess mortality outcomes. Food frequency questionnaires will unavoidably include some inaccuracy (for example, inaccurate recall or estimation of intake).
However, the researchers did attempt to validate the information through a series of 24-hour recalls.
The researchers have adjusted their analyses for age, study centre, weight and height, smoking and alcohol intake, overall energy intake, physical activity levels and educational level.
However, as the authors rightly conclude, the main limitation of the study is that it cannot completely exclude the possibility of residual confounding – that is, that the effects of these demographic, health and lifestyle factors, or others unmeasured, have not been fully accounted for.
These limitations apart, the study provides reasonably good evidence to support the importance of eating a healthy balanced diet, containing a high amount of fruit and vegetables. At the same time, it is important to moderate your consumption of foods high in salt, fat and sugar, which includes many processed foods.
The occasional bacon sandwich or full English breakfast probably won’t do significant damage to your health. But these should be occasional treats and not a staple of your diet. 
Analysis by Bazian. Edited by NHS Choices. Follow Behind the Headlines on Twitter.



reposted from: Cancer Research UK
crabsallover highlightskey pointscomments / links.


Cancer News
Limiting processed meat consumption 'could prevent three per cent of premature deaths'
Thursday 7 March 2013

If everyone ate less than 20g of processed meat a day, there would be a three per cent drop in premature deaths from cancer and heart disease, according to new European research.

High consumption of red and processed meat has previously been linked to an increased risk of several types of cancer, particularly bowel cancer, as well as cardiovascular diseases.

The European Prospective Investigation into Cancer and Nutrition (EPIC) study - part-funded by Cancer Research UK - is following the diets, medical records and death certificates of half a million men and women from 10 European countries.

Its latest analysis, published in the journal BMC Medicine, looked at patterns of consumption of meat among participants, and how this related to their cause of death.

Over an average of nearly 13 years, 26,344 study participants died. Of these, 5,556 died of cardiovascular diseases, 9,861 of cancer, 1,068 of respiratory diseases, 715 of digestive tract diseases, and 9,144 of other causes.

Analysis showed that a person's risk of premature death from cancer or heart disease increased with the amount of processed meat they ate, even once other lifestyle variables were factored in.

No link was seen between red meat or poultry.

Those who ate the most processed meat also ate the fewest fruit and vegetables and were more likely to smoke, while men who ate a lot of meat also tended to drink heavily, the study found.

Yinka Ebo, senior health information officer at Cancer Research UK, said: "There's a clear link between eating too much processed meat and bowel cancer, but this study suggests that cutting down on these meats could also reduce the risk of dying prematurely.

"There's no need to abandon meat altogether, but if you eat a lot of processed meat it's worth cutting down by eating smaller and fewer portions, or eating fish, poultry or beans instead," she added.

Copyright Press Association 2013

Rohrmann S, et al. Meat consumption and mortality - results from the European Prospective Investigation into Cancer and Nutrition (2013) BMC Medicine



Nonparametric regression curve for the relation of processed meat intake at recruitment with all-cause mortality, European Prospective Investigation into Cancer and Nutrition (EPIC), 1992-2009. Solid line, effect estimate; dotted lines, 95 percent confidence interval.
Rohrmann et al. BMC Medicine 2013 11:63   doi:10.1186/1741-7015-11-63

Sunday, 30 December 2012

Cardiovascular Disease Risk Prediction Charts

reposted from: http://heartuk.org.uk/health-professionals/resources/risk-charts
crabsallover highlightskey pointscomments / links.


Risk charts

How to use the Cardiovascular Disease Risk Prediction Charts* for Primary Prevention

These charts are for estimating cardiovascular disease (CVD) risk (non-fatal myocardial infarction [MI] and stroke, coronary and stroke death and new angina pectoris) for individuals who have not already developed coronary heart disease (CHD) or other major atherosclerotic disease. They are an aid to making clinical decisions about how intensively to intervene on lifestyle and whether to use antihypertensive, lipid lowering medication and aspirin. The use of these charts is not appropriate for the following patients groups.

  • Those with: CHD or other major atherosclerotic disease 
  • Familial hypercholesterolaemia or other inherited dyslipidaemias 
  • Chronic renal dysfunction 
  • Type 1 and 2 diabetes mellitus





The charts should not be used to decide whether to introduce antihypertensive medication when blood pressure (BP) is persistently at or above 160/100 or when target organ damage (TOD) due to hypertension is present. In both cases antihypertensive medication is recommended regardless of CVD risk.

Similarly the charts should not be used to decide whether to introduce lipid-lowering medication when the ratio of serum total to high density lipoprotein (HDL) cholesterol exceeds 7. Such medication is generally then indicated regardless of estimated CVD risk.

To estimate an individual’s absolute 10 year risk of developing CVD choose the table for his or her gender, smoking status (smoker/non-smoker) and age. Within this square define the level of risk according to the point where the coordinates for systolic blood pressure (SBP) and the ratio of total cholesterol to HDL-cholesterol meet. If no HDL cholesterol result is available, then assume this is 1.00mmol/l and the lipid scale can be used for total serum cholesterol alone.

Higher risk individuals (red areas) are defined as those whose 10 year CVD risk exceeds 20%, which is approximately equivalent to the CHD risk of >15% over the same period indicated by the previous version of these charts. As a minimum those at highest CVD risk (greater than 30% shown by the line within the red area) should be targeted and treated now. When resources allow, others with a CVD risk of >20% should be progressively targeted.

The chart also assists in the identification of individuals whose 10 year CVD risk moderately increased in the range 10-20% (orange area) and those in whom risk is lower than 10% over 10 years (green area).

Smoking status should reflect lifetime exposure to tobacco and not simply tobacco use at the time of assessment. For example, those who have given up smoking within 5 years should be regarded as current smokers for the purposes of the charts.

The initial BP and the first random (non-fasting) total cholesterol and HDL cholesterol can be used to estimate an individual’s risk. However, the decision on using drug therapy should generally be based on repeat risk factor measurements over a period of time.

Men and women do not reach the level of risk predicted by the charts for the three age bands until they reach the ages 49, 59, and 69 years respectively. Everyone aged 70 years and over should be considered at higher risk. The charts will overestimate current risk most in the under forties. Clinical judgement must be exercised in deciding on treatment in younger patients. However, it should be recognised that BP and cholesterol tend to rise most and HDL cholesterol to decline most in younger people already possessing adverse levels. Thus untreated, their risk at the age 49 years is likely to be higher than the projected risk shown on the age-less-than 50 years chart.

These charts (and all other currently available methods of CVD risk prediction) are based on groups of people with untreated levels of BP, total cholesterol and HDL cholesterol. In patients already receiving antihypertensive therapy in whom the decision is to be made about whether to introduce lipid-lowering medication or vice versa the charts can act as a guide, but unless recent pre-treatment risk factor values are available it is generally safest to assume that CVD risk is higher than that predicted by current levels of BP or lipids on treatment.

CVD risk is also higher than indicated in the charts for:-

  • Those with a family history of premature CVD or stroke (male first degree relatives aged <55 years and female first degree relatives aged <65 years) which increases the risk by a factor of approximately 1.5 
  • Those with raised triglyceride levels 
  • Women with premature menopause 
  • Those who are not yet diabetic, but have impaired fasting glucose (6.1-6.9mmol/l) 
  • In some ethnic minorities the risk charts underestimate CVD risk, because they have not been validated in these populations. For example, in people originating from the Indian subcontinent it is safest to assume that the CVD risk is higher than predicted from the charts (1.5 times). 
  • The charts may be used to illustrate the direction of impact of risk factor intervention on estimated level of CVD risk. However, such estimates are crude and are not based on randomised trial evidence. Nevertheless, this approach maybe helpful in motivating appropriate intervention. 
  • The charts are primarily to assist in directing intervention to those who typically stand to benefit most. 

*Cardiovascular Disease Risk Prediction Chart reproduced with permission from The University of Manchester Department of Medical Illustration, Manchester Infirmary.


Monday, 17 September 2007

Brits 'dying not to do exercise'

reposted from: http://news.bbc.co.uk/1/hi/health/6994632.stm

Brits 'dying not to do exercise'
Man sat watching TV
Lack of exercise increases the risk of heart disease and cancer
Most UK adults are so unwilling to exercise that not even the threat of an early death is enough to get them off the sofa,
a survey suggests.

Only 38% of people questioned by YouGov said they would do more exercise if their life depended on it.

And British Heart Foundation figures show only a third of people manage to do enough exercise to achieve the minimum recommended amount.

Experts warned inactivity is dangerous even in those who are a healthy weight.

Among the 2,100 people surveyed, brisk walking was found to be the favourite way of getting exercise - before dancing, swimming or going to the gym.

Physical activity and obesity are two different risk factors so even if you're lean, if you're inactive you increase your risk of cancer and cardiovascular disease
Dr David Haslam, National Obesity Forum

However, only 4% said they found exercise fun.

A greater inspiration was exercising to change body shape, particularly among women and young adults.

Almost a third of 18 to 24-year-olds reported they would do more exercise if they saw an unflattering photo of themselves or were told they looked fat.

Other less predictable forms of motivation to work out included fancying someone at the gym.

But

only 13% of men and 7% of women said keeping a healthy heart was their main motivator.

Excuses for not exercising were found to be always close at hand - from not having enough time to the one in seven who blame bad weather for not doing enough physical activity.

Deadly serious

The British Heart Foundation, which

is launching a campaign to encourage people to up their heart rate for 30 minutes a day,
says that
someone dies every 15 minutes as a direct result of physical inactivity.

Dr Mike Knapton, director of prevention and care at the BHF, said it was a "deadly serious" problem.

"With our busy lifestyles and labour-saving devices we've stopped getting the exercise our bodies desperately need.

"For many people, exercise has become an ugly word, something to avoid at all costs - but you'd be amazed how easy it is to up the tempo of your heartbeat.

"Just 30 minutes a day will do you and your heart the world of good."

The government recommends a minimum of 30 minutes of moderate-intensity physical activity five times a week.

Dr David Haslam, clinical director of the National Obesity Forum, said it made for depressing reading but confirmed what had been shown in clinical trials, where even those who had a heart attack did not change their lifestyles.

"Children instinctively exercise when left to their own devices, but they don't because they're stopped from doing that by the school curriculum and parents scared of child abductors and murderers lurking on every corner.

"So, if it doesn't become a habit, you're not going to work hard to go against the tide and introduce it as an adult."

He added that exercise could be incorporated into everyday life.

"Physical activity and obesity are two different risk factors, so even if you're lean, if you're inactive you increase your risk of cancer and cardiovascular disease,"
he said.

Friday, 9 February 2007

The evidence I've considered for Statin treatment - to reduce cholesterol & risk of Cardiovascular disease

this blog copied in full from my crabsallover blog February 2007.

This week SIGN (Scottish Intercollegiate Guidelines Network) published Guideline No 97 - Risk estimation and prevention of Cardiovascular Disease (CVD):-
Cardiovascular Disease (CVD) is any disease which affects the heart and blood vessels (examples include coronary heart disease, peripheral heart disease, stroke and heart failure).

Coronary Heart Disease (CHD) is a disease of the heart and coronary arteries caused by a build of fatty materials in the blood vessels which supply the heart with oxygen. This can cause a heart attack, or chest pain or angina.

My risk of CVD in the next 10 years is 1 in 12.5 (8%) according to my 'ASSIGN' score (table 1). So for every 1000 persons with my CVD risk, 80 will have a CVD event in the next 10 years.

Other Factors - not accounted for by 'ASSIGN' score
  • At 102cm I have borderline abdominal obesity (defined as greater or equal to 102cm waist measurement in men). (4.7 pg 15)
  • waist hip ratio is 102cm/98cm = 1.04 (<0.95>
  • I'm overweight BMI >25 (12st 6 pounds, height 5'7.5", BMI 27.5).
I've reviewed Statins in several other blogs. Statins inhibit cholesterol synthesis in the liver, activate hepatocyte LDL receptors and increase uptake of LDL from the circulation (9.3 pg 28)

In October 2006 my blood tests were:
  • 5.1 mmol/l total cholesterol (NHS normal: <=5.0)
  • 3.0 mmol/l LDL 'bad' cholesterol
  • 1.02 mmol/l HDL 'good' cholesterol (normal >1.03) (4.7 pg 15)
  • total cholesterol/HDL cholesterol ratio = 5.0
  • Blood pressure = 130 systolic/70 diastolic (normal <130/85)
    • On 30th April 2007 my figure (ex Poole Hospital 110/70)
  • 5.9 mmol /l glucose
Grades of evidence The SIGN study grades evidence ranging from High quality meta-analyses (1++) to Expert Opinion (4). It grades recommendations from A to D based on this evidence. (page 2, Full Guideline) The report defines people in a 'High Risk' category if they have a >=20% risk of CVD over the next 10 years. For those with 1% annual risk of CVD ( viz. 10% over 10 years) benefits have been shown using statins (3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) Reductase inhibitors). Annual CVD is 1% in USA and Europe. So most middle aged men and women could benefit from a statin and CVD reduction. (Full Guideline (FG) 2.4 pg 11) 8.2 Aspirin Antiplatelet therapy with Aspirin reduces Myocardial Infarction (heart attack) risk but increases stroke and major gastrointestinal bleeding risk. P S Sanmuganathan et al in Heart85:265-271 2001; concluded "Aspirin treatment for primary prevention is safe and worthwhile at coronary event risk greater than 1.5%/year; safe but of limited value at coronary risk 1%/year; and unsafe at coronary event risk 0.5%/year." With my 8% over 10 year CVD risk, Aspirin is of limited value or unsafe. 9 Lipid Lowering Low density Lipoprotein (LDL) makes up 60-70% of serum cholesterol. The Friedwald equation LDL = TC-HDL-(TG/2.2) (9.2 pg 32) Statins reduce Total Cholesterol TC by approx. 20% or 1mmol and LDL Cholesterol by 30% (9.3, pg 28) with a 30% reduction in CHD mortality (9.3 pg 29). With each doubling of the dose of a statin LDL levels fall by 6%. A reduction of 1.6 mmol/l halves the risk of CHD events after 2 years and this reduction can be achieved with standard doses of statins. (9.4 pg 30, table 8) My 8% (1 in 12.5) risk of CVD (table 1, total cholesterol 5.1 mmol/l) could be reduced to a 6% risk (1 in 17) (table 2, total cholesterol 3.88 mmol/l) - a 25% risk reduction. 80 people per thousand, like me, will have CardioVascular Disease over 10 years. By taking Statins that risk is reduced to 60 people with CVD. Mild muscle pains or other adverse effects (eg fever, malaise) may require reduction in statin levels or change of statin type whilst severe side effects will require statin therapy to be discontinued. (para 9.6, pg 36). Current NHS target for individuals at high cardiovascular risk is a TC level of less than 5 mmol. Reducing this target to 4.5 or 4.0 mmol/l would have major resource implications for NHS (9.7 pg 32). Zocor (simvastatin, 10mg per day) is available from Boots over the counter for £8 per month. HDL Cholesterol my level of 1.02 mmol/l HDL Cholesterol is low and may require treatment with Fibrates (raises levels 10-15%,) (9.10.2 pg 39) or Nicotinic Acid (raises levels 15-35%) (9.10.3 pg 40) 9.8 Safety of Statins Statins are safe. No increase in cancer levels has been found. Raised levels of liver enzymes (aspartate and alanine aminotransferase) occur in 1% cases which is completely reversible when treatment is withdrawn. Minor muscle discomfort is common though the incidence varies. Rare more serious Myopathy with raised creatine kinase occurs in 0.1% cases. In 0.01% cases Rhabdomyalysis (renal failure) occurs. Withdrawal of treatment leads to recovery in a majority of cases but death can occur if patient is receiving several drug treatments or experiencing multiple symptoms. Statins may possibly interact with other medications eg fibrates (niacin, nicotinic acid). Inhibitors of cytochrome P450 and grapefruit juice may increase Myopathy risk. Atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin are licensed for use in UK. Annex 2 pg 62 Joint British Societies (JBS2 - reference 28) proposed total cholesterol target of <4mmol/l size="4">Annex 3 pg 65 Creatine Kinase (CK) baseline pretreatment level might be useful to monitor possible muscular symptoms. Annex 4 pg 66 Liver transaminase levels advisable prior to statin treatment, 3 months after treatment and when dose level is increased. This indicates potential for jaundice, malaise, fatigue, lethargy etc. Annex 5 pg 67 Assessment of renal function is advisable before starting statin therapy. Test for serum creatinine and proteinuria. Conclusions for my health
  • current risk of CVD is 8% - table 1
  • Aspirin is of limited value or unsafe
  • Statins are safe and should be taken daily after
  • a baseline checkup (total cholesterol, LDL, HDL, Triglycerides, blood pressure, Creatine Kinase, liver transaminase, serum creatinine and proteinuria)
  • Statin treatment targets
    • 30% reduction in LDL cholesterol (from 3 to 1.9 mmol/l)
    • 24% reduction in total cholesterol (from 5.1 to 3.88 mmol/l)
    • reduce risk of CVD by 25% - from 1 in 12 (8%) to 1 in 17 (6%) over 10 years - table 2.
  • Fibrates or Nicotinic acid treatment targets (after initial statin treatment)
    • Reduce CVD risk to 5% (1 in 20) by increasing HDL cholesterol to medium levels (1.34 mmol/l) - table 3
    • Reduce CVD risk to 4% (1 in 25) by increasing HDL cholesterol to high levels (1.73 mmol/l) - table 4
  • Reduce CVD risk to 3% (1 in 33) by reducing systolic blood pressure from 130 to 108 mmHg by improving diet and increasing exercise - table 5
Table 1: Baseline 8% risk Table 2: 6% risk after Statin treatment Table 3: 5% risk after treatment to give medium HDL cholesterol levels Table 4: 4% risk after treatment to give high HDL cholesterol levels

Table 5: 3% risk after treatment to give low blood pressure

The evidence I've considered for Statin treatment - to reduce cholesterol & risk of Cardiovascular disease

This week SIGN (Scottish Intercollegiate Guidelines Network) published Guideline No 97 - Risk estimation and prevention of Cardiovascular Disease (CVD):-
Cardiovascular Disease (CVD) is any disease which affects the heart and blood vessels (examples include coronary heart disease, peripheral heart disease, stroke and heart failure).

Coronary Heart Disease (CHD) is a disease of the heart and coronary arteries caused by a build of fatty materials in the blood vessels which supply the heart with oxygen. This can cause a heart attack, or chest pain or angina.

My risk of CVD in the next 10 years is 1 in 12.5 (8%) according to my 'ASSIGN' score (table 1). So for every 1000 persons with my CVD risk, 80 will have a CVD event in the next 10 years.

Other Factors - not accounted for by 'ASSIGN' score
  • At 102cm I have borderline abdominal obesity (defined as greater or equal to 102cm waist measurement in men). (4.7 pg 15)
  • waist hip ratio is 102cm/98cm = 1.04 (<0.95>
  • I'm overweight BMI >25 (12st 6 pounds, height 5'7.5", BMI 27.5).
I've reviewed Statins in several other blogs. Statins inhibit cholesterol synthesis in the liver, activate hepatocyte LDL receptors and increase uptake of LDL from the circulation (9.3 pg 28)

In October 2006 my blood tests were:
  • 5.1 mmol/l total cholesterol (NHS normal: <=5.0)
  • 3.0 mmol/l LDL 'bad' cholesterol
  • 1.02 mmol/l HDL 'good' cholesterol (normal >1.03) (4.7 pg 15)
  • total cholesterol/HDL cholesterol ratio = 5.0
  • Blood pressure = 130 systolic/70 diastolic (normal <130/85)
    • On 30th April 2007 my figure (ex Poole Hospital 110/70)
  • 5.9 mmol /l glucose
Grades of evidence The SIGN study grades evidence ranging from High quality meta-analyses (1++) to Expert Opinion (4). It grades recommendations from A to D based on this evidence. (page 2, Full Guideline) The report defines people in a 'High Risk' category if they have a >=20% risk of CVD over the next 10 years. For those with 1% annual risk of CVD ( viz. 10% over 10 years) benefits have been shown using statins (3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) Reductase inhibitors). Annual CVD is 1% in USA and Europe. So most middle aged men and women could benefit from a statin and CVD reduction. (Full Guideline (FG) 2.4 pg 11) 8.2 Aspirin Antiplatelet therapy with Aspirin reduces Myocardial Infarction (heart attack) risk but increases stroke and major gastrointestinal bleeding risk. P S Sanmuganathan et al in Heart85:265-271 2001; concluded "Aspirin treatment for primary prevention is safe and worthwhile at coronary event risk greater than 1.5%/year; safe but of limited value at coronary risk 1%/year; and unsafe at coronary event risk 0.5%/year." With my 8% over 10 year CVD risk, Aspirin is of limited value or unsafe. 9 Lipid Lowering Low density Lipoprotein (LDL) makes up 60-70% of serum cholesterol. The Friedwald equation LDL = TC-HDL-(TG/2.2) (9.2 pg 32) Statins reduce Total Cholesterol TC by approx. 20% or 1mmol and LDL Cholesterol by 30% (9.3, pg 28) with a 30% reduction in CHD mortality (9.3 pg 29). With each doubling of the dose of a statin LDL levels fall by 6%. A reduction of 1.6 mmol/l halves the risk of CHD events after 2 years and this reduction can be achieved with standard doses of statins. (9.4 pg 30, table 8) My 8% (1 in 12.5) risk of CVD (table 1, total cholesterol 5.1 mmol/l) could be reduced to a 6% risk (1 in 17) (table 2, total cholesterol 3.88 mmol/l) - a 25% risk reduction. 80 people per thousand, like me, will have CardioVascular Disease over 10 years. By taking Statins that risk is reduced to 60 people with CVD. Mild muscle pains or other adverse effects (eg fever, malaise) may require reduction in statin levels or change of statin type whilst severe side effects will require statin therapy to be discontinued. (para 9.6, pg 36). Current NHS target for individuals at high cardiovascular risk is a TC level of less than 5 mmol. Reducing this target to 4.5 or 4.0 mmol/l would have major resource implications for NHS (9.7 pg 32). Zocor (simvastatin, 10mg per day) is available from Boots over the counter for £8 per month. HDL Cholesterol my level of 1.02 mmol/l HDL Cholesterol is low and may require treatment with Fibrates (raises levels 10-15%,) (9.10.2 pg 39) or Nicotinic Acid (raises levels 15-35%) (9.10.3 pg 40) 9.8 Safety of Statins Statins are safe. No increase in cancer levels has been found. Raised levels of liver enzymes (aspartate and alanine aminotransferase) occur in 1% cases which is completely reversible when treatment is withdrawn. Minor muscle discomfort is common though the incidence varies. Rare more serious Myopathy with raised creatine kinase occurs in 0.1% cases. In 0.01% cases Rhabdomyalysis (renal failure) occurs. Withdrawal of treatment leads to recovery in a majority of cases but death can occur if patient is receiving several drug treatments or experiencing multiple symptoms. Statins may possibly interact with other medications eg fibrates (niacin, nicotinic acid). Inhibitors of cytochrome P450 and grapefruit juice may increase Myopathy risk. Atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin are licensed for use in UK. Annex 2 pg 62 Joint British Societies (JBS2 - reference 28) proposed total cholesterol target of <4mmol/l size="4">Annex 3 pg 65 Creatine Kinase (CK) baseline pretreatment level might be useful to monitor possible muscular symptoms. Annex 4 pg 66 Liver transaminase levels advisable prior to statin treatment, 3 months after treatment and when dose level is increased. This indicates potential for jaundice, malaise, fatigue, lethargy etc. Annex 5 pg 67 Assessment of renal function is advisable before starting statin therapy. Test for serum creatinine and proteinuria. Conclusions for my health
  • current risk of CVD is 8% - table 1
  • Aspirin is of limited value or unsafe
  • Statins are safe and should be taken daily after
  • a baseline checkup (total cholesterol, LDL, HDL, Triglycerides, blood pressure, Creatine Kinase, liver transaminase, serum creatinine and proteinuria)
  • Statin treatment targets
    • 30% reduction in LDL cholesterol (from 3 to 1.9 mmol/l)
    • 24% reduction in total cholesterol (from 5.1 to 3.88 mmol/l)
    • reduce risk of CVD by 25% - from 1 in 12 (8%) to 1 in 17 (6%) over 10 years - table 2.
  • Fibrates or Nicotinic acid treatment targets (after initial statin treatment)
    • Reduce CVD risk to 5% (1 in 20) by increasing HDL cholesterol to medium levels (1.34 mmol/l) - table 3
    • Reduce CVD risk to 4% (1 in 25) by increasing HDL cholesterol to high levels (1.73 mmol/l) - table 4
  • Reduce CVD risk to 3% (1 in 33) by reducing systolic blood pressure from 130 to 108 mmHg by improving diet and increasing exercise - table 5
Table 1: Baseline 8% risk Table 2: 6% risk after Statin treatment Table 3: 5% risk after treatment to give medium HDL cholesterol levels Table 4: 4% risk after treatment to give high HDL cholesterol levels

Table 5: 3% risk after treatment to give low blood pressure